 Amicus Therapeutics Inc NASDAQ: FOLD has completed a Type B Pre-Biologics License Application BLA meeting with the FDA for AT-GAA cipaglucosidase alfa co-administered with miglustat for Pompe disease. Based on this formal pre-BLA meeting and the final written communication received from the FDA, Amicus intends to complete the rolling submission for cipaglucosidase alfa and submit a marketing application for miglustat. 